BCL2 (Ab-70) Antibody

What is BCL2 (Ab-70) Antibody and what epitope does it recognize?

BCL2 (Ab-70) Antibody is a rabbit-produced affinity-isolated antibody that specifically binds to Bcl-2 protein phosphorylated at the Ser70 site (pS70). The antibody targets a peptide sequence around amino acids 68-72 (R-T-S-P-L) of the Bcl-2 protein . Bcl-2 is a ~26 kDa intracellular, integral membrane protein found primarily in the nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane . It functions as an anti-apoptotic member of the Bcl-2 family, playing a crucial role in regulating programmed cell death through controlling mitochondrial membrane permeability.

How does BCL2 (Ab-70) Antibody differ from other BCL2 antibodies?

The key distinction of BCL2 (Ab-70) Antibody is its specificity for the phosphorylated form of Bcl-2 at Ser70. This differentiates it from antibodies that recognize total Bcl-2 regardless of phosphorylation status . Research has demonstrated that antibodies targeted at different Bcl-2 epitopes (such as clones 124, E17, and SP66) detect varying levels of protein expression in tissues . Notably, the standard clone 124 antibody failed to detect Bcl-2 expression in the majority of translocation-positive and amplification-positive diffuse large B-cell lymphoma cases where phosphorylation of Bcl-2 at Ser70 was common . This makes phospho-specific antibodies particularly valuable for certain experimental contexts.

What are the recommended applications for BCL2 (Ab-70) Antibody?

BCL2 (Ab-70) Antibody has been validated for multiple experimental applications with specific recommended dilutions:

Since applications may vary between laboratories, each investigator should titrate the reagent to obtain optimal results for their specific experimental conditions .

How should BCL2 (Ab-70) Antibody be stored and handled?

For optimal performance, BCL2 (Ab-70) Antibody should be stored at -20°C . The antibody is typically supplied as a buffered aqueous solution in phosphate-buffered saline containing 0.02% sodium azide and 50% glycerol . Repeated freeze-thaw cycles should be avoided as they can compromise antibody performance. When handling the antibody, it's important to note the product safety information regarding sodium azide, which yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing .

How does phosphorylation at Ser70 affect Bcl-2's anti-apoptotic function?

Phosphorylation of Bcl-2 at Ser70 significantly enhances its anti-apoptotic activity through several mechanisms:

• Enhanced binding to pro-apoptotic proteins: Surface plasmon resonance studies have demonstrated that phosphorylated Bcl-2 exhibits increased binding affinity to pro-apoptotic proteins Bim and Bak compared to unmodified Bcl-2 .

• Conformational changes: Phosphorylation induces a readily detectable conformational change in the loop domain of Bcl-2, which facilitates its interactions with binding partners .

• Increased protection against chemotherapeutic agents: Bcl-2 phosphorylation at Ser70 or mutations that mimic this phosphorylation (S70E) afford greater protection against several chemotherapeutic agents in cellular models .

• Mitotic regulation: Phosphorylation of Bcl-2 at Ser70 has been shown to be a mitotic marker, with increased binding to Bim observed during mitosis when Bcl-2 is endogenously phosphorylated .

• Autophagy promotion: Recent studies have implicated Ser70 phosphorylation in promoting autophagy, adding another dimension to Bcl-2's cellular functions .

These findings collectively provide a mechanistic basis for the enhanced anti-apoptotic activity of phosphorylated Bcl-2 and explain why phospho-specific antibodies are important research tools.

What methods can be used to validate BCL2 (Ab-70) Antibody specificity?

To ensure experimental rigor, multiple validation approaches should be employed:

Using these complementary approaches provides robust validation of antibody specificity and phospho-selectivity.

How can researchers differentiate between phosphorylated and non-phosphorylated Bcl-2?

Distinguishing between phosphorylated and non-phosphorylated Bcl-2 requires strategic experimental approaches:

• Parallel antibody staining: Use BCL2 (Ab-70) Antibody alongside antibodies that recognize total Bcl-2 regardless of phosphorylation status (e.g., clone EPR17509) . The ratio of phosphorylated to total Bcl-2 provides quantitative information about the phosphorylation state.

• Phosphatase treatment controls: Treating parallel samples with phosphatases eliminates phospho-specific signals, confirming that detection is phosphorylation-dependent.

• Phosphorylation site mapping: Since Bcl-2 contains multiple phosphorylation sites (Thr56, Ser70, Thr74, and Ser87) , using site-specific antibodies helps distinguish which sites are modified under different conditions.

• Functional correlation: The enhanced binding of phosphorylated Bcl-2 to Bim and Bak can serve as a functional readout of phosphorylation status through co-immunoprecipitation experiments .

• Cell cycle synchronization: Since Bcl-2 Ser70 phosphorylation increases during mitosis, comparing cells at different cell cycle stages can help validate phosphorylation-specific detection .

What factors influence false positives or false negatives when using BCL2 (Ab-70) Antibody?

Several factors can affect the accuracy of BCL2 (Ab-70) Antibody detection:

Potential false negatives:

• Rapid dephosphorylation during sample preparation (use phosphatase inhibitors)

• Inadequate antigen retrieval in fixed tissues (optimize retrieval protocols)

• Epitope masking by protein-protein interactions (consider detergent conditions)

• Low expression levels (increase antibody concentration or use amplification systems)

Potential false positives:

• Cross-reactivity with similar phosphorylated motifs in other proteins (validate with appropriate controls)

• Non-specific binding at high antibody concentrations (titrate for optimal signal-to-noise ratio)

• Detection of phosphorylation introduced during apoptosis rather than physiological signaling

• Artificial phosphorylation during sample handling (maintain samples at cold temperatures)

Research has shown that phosphorylation of Bcl-2 at Ser70 can affect detection by certain antibodies, with the standard clone 124 failing to detect Bcl-2 in cases where phosphorylation is present . This highlights the importance of using phospho-specific antibodies when studying modified forms of the protein.

How can BCL2 (Ab-70) Antibody be used to investigate chemoresistance mechanisms?

The role of Bcl-2 phosphorylation in chemoresistance can be investigated using BCL2 (Ab-70) Antibody through several sophisticated approaches:

• Correlation with treatment response: Compare phospho-Bcl-2 levels in sensitive versus resistant cell lines or patient samples using immunoblotting or immunohistochemistry with the antibody .

• Temporal dynamics during treatment: Monitor changes in Bcl-2 phosphorylation before, during, and after chemotherapy treatment to establish whether phosphorylation is a cause or consequence of resistance.

• Combination with targeted therapies: Use the antibody to assess how Bcl-2 phosphorylation changes during treatment with BH3 mimetics (e.g., navitoclax, ABT-199) that disrupt Bcl-2/Bim binding, which has been shown to enhance taxane sensitivity .

• Signaling pathway analysis: Since Bcl-2 phosphorylation is mediated by JNK , combine BCL2 (Ab-70) Antibody with inhibitors of this pathway to determine functional connections to resistance mechanisms.

• Protein interaction studies: Use the antibody in co-immunoprecipitation experiments to identify differential binding partners of phosphorylated Bcl-2 in resistant versus sensitive cells.

Research has demonstrated that phosphorylated Bcl-2 exhibits enhanced binding to pro-apoptotic proteins Bim and Bak, providing greater protection against several chemotherapeutic agents . Disruption of this binding with BH3 mimetics enhances cytotoxicity of paclitaxel , suggesting a mechanistic link between phosphorylation status and treatment response.

What methodological considerations are important for subcellular localization studies?

When investigating the subcellular distribution of phosphorylated Bcl-2 using BCL2 (Ab-70) Antibody, researchers should consider:

• Fixation and permeabilization optimization: Different fixatives and permeabilization methods can affect epitope accessibility, particularly for phosphorylated proteins. Compare cross-linking (e.g., paraformaldehyde) versus precipitating (e.g., methanol) fixatives.

• Co-localization markers: Include established markers for subcellular compartments where Bcl-2 is found (nuclear envelope, endoplasmic reticulum, and outer mitochondrial membrane) in multiplexed immunofluorescence studies.

• Fractionation controls: When performing subcellular fractionation followed by Western blotting, verify fraction purity using compartment-specific markers.

• Resolution considerations: Super-resolution microscopy techniques may be necessary to distinguish between closely adjacent structures like the nuclear envelope and ER.

• Quantitative co-localization analysis: Apply appropriate statistical methods to quantify the degree of co-localization between phospho-Bcl-2 and subcellular markers.

• Functional correlation: Correlate subcellular distribution of phosphorylated Bcl-2 with functional outcomes such as localized autophagy or apoptosis resistance.

A key consideration is that phosphorylation may affect Bcl-2's subcellular distribution or its detection in certain compartments, requiring careful validation with multiple approaches.

How can BCL2 (Ab-70) Antibody be integrated into multiplexed detection systems?

Incorporating BCL2 (Ab-70) Antibody into multiplexed detection requires careful optimization:

For studying apoptotic mechanisms, a useful multiplex panel might include BCL2 (Ab-70) Antibody alongside antibodies against total Bcl-2, interacting partners like Bim and Bak , and downstream effectors of apoptosis.

What are the most effective quantification methods for measuring changes in Bcl-2 phosphorylation?

Quantitative assessment of Bcl-2 phosphorylation requires rigorous methodological approaches:

• Ratiometric analysis: Normalize phospho-Bcl-2 signal (detected with BCL2 (Ab-70) Antibody) to total Bcl-2 signal to account for expression level differences between samples.

• Phosphatase-treated controls: Include phosphatase-treated samples as a baseline to calculate fold-change in phosphorylation.

• Multi-parameter flow cytometry: Combine BCL2 (Ab-70) Antibody with antibodies against total Bcl-2 and other relevant markers for single-cell resolution of phosphorylation status across cellular subpopulations.

• Quantitative image analysis: For tissue sections or cellular imaging, apply automated image analysis with cellular segmentation to extract phosphorylation intensity data at the single-cell level.

• Calibration standards: When possible, include samples with known phosphorylation levels as calibration standards.

• Statistical validation: Apply appropriate statistical methods to determine significance of observed changes, considering both biological and technical variability.

Research has shown that Bcl-2 phosphorylation increases during mitosis and affects binding to pro-apoptotic partners , making cell cycle stage an important variable to control in quantitative studies.

How can BCL2 (Ab-70) Antibody be used in developing novel therapeutic approaches?

BCL2 (Ab-70) Antibody can contribute to therapeutic development in several ways:

• Biomarker identification: Use the antibody to determine whether Bcl-2 phosphorylation status correlates with response to BH3 mimetics or other cancer therapies, potentially identifying patient subgroups most likely to benefit.

• Combination therapy rationalization: Since disruption of Bcl-2/Bim binding with navitoclax or ABT-199 enhances paclitaxel cytotoxicity , the antibody can help monitor how different drug combinations affect Bcl-2 phosphorylation and function.

• Resistance mechanism elucidation: Apply the antibody to study whether changes in Bcl-2 phosphorylation contribute to acquired resistance to targeted therapies.

• Target validation: Use the antibody to validate whether potential therapeutic compounds affect Bcl-2 phosphorylation status as part of their mechanism of action.

• Pharmacodynamic monitoring: Employ the antibody in preclinical or clinical studies to determine whether drugs targeting relevant kinases (e.g., JNK inhibitors ) effectively reduce Bcl-2 phosphorylation in vivo.